Fund moves
5.8%Stake · was 5.8%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
TRAX · NASDAQ · Pharmaceutical Preparations · No 10-K yet
First Tracks Biotherapeutics (TRAX) · oqro.io/stocks/TRAX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$44.50+0.93 (+2.13%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+139.2% (+$25.90) from Apr 20, 2026 to Nov 18, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $18.60 on Apr 20, 2026 to $44.50 on Nov 18, 2026 (+139.2%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in San Diego, CA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$1.87B
Short interest: 5.06M shares sold short (12.0% of shares outstanding), −27.3% vs the previous count, 6.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
−$17.1M
This quarter −$17.1M, a year earlier −$30.7M
Net debt
—
Debt —, cash $156M, at Sep 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No open-market purchase by an insider of First Tracks Biotherapeutics is on record in SEC filings since 2006.
No open-market sale by an insider of First Tracks Biotherapeutics (TRAX) was filed with the SEC in the last 90 days.
No trade in First Tracks Biotherapeutics (TRAX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Against the S&P 500 over the year
Since Apr 20, 2026, TRAX is up 139.2% and the index fund is up 3.0%: 136 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much TRAX moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
FMR LLC
Schedule 13G: passive · filed Nov 6, 2026 · 6.3M shares
BlackRock, Inc.
Schedule 13G: passive · filed Oct 27, 2026 · 2.56M shares
Adage Capital Management, L.P.
Schedule 13G: passive · filed Nov 12, 2026 · 2.08M shares
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Fails to deliver: 71K shares (about $2.42M) were not delivered on time for settlement on Oct 13, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.